L-ornithine-L-aspartate (LOLA): the urea cycle, glutamine and hyperammonemia

L-ornithine-L-aspartate supplies two amino acids that participate in nitrogen metabolism. Ornithine is recycled in the urea cycle; aspartate donates the second nitrogen of urea and links transamination to mitochondrial redox metabolism. Their availability can support ammonia handling when the necessary enzymes, transporters and viable tissues remain functional. This is different from demonstrating that LOLA directly binds and activates human carbamoyl phosphate synthetase 1 (CPS1). The obligatory CPS1 activator is N-acetylglutamate (NAG), produced by N-acetylglutamate synthase (NAGS); arginine activates mammalian NAGS. The distinction matters because a substrate supplement cannot automatically overcome loss of liver tissue, portosystemic shunting or an inherited urea-cycle defect (Bachmann et al., 1982; Caldovic et al., 2006; de Cima et al., 2015).

Clinical evidence also requires separate questions. Lower ammonia, faster improvement in hepatic encephalopathy, prevention of recurrence and longer survival are different outcomes. Trials in cirrhosis have produced useful signals, including adjunctive treatment of severe encephalopathy, but effects depend on the population, comparator and endpoint. A randomized trial in acute liver failure did not establish a survival or ammonia benefit. Neither a plausible biochemical pathway nor an isolated positive trial proves a universal treatment effect.

Chemical identity, absorption and exposure

LOLA is a 1:1 salt of L-ornithine and L-aspartic acid, rather than a peptide joining them by a covalent bond. Both amino acids have the natural L configuration, corresponding to the S configuration at their alpha-carbon. The molecular composition of the anhydrous 1:1 combination is:

$$\mathrm{C_5H_{12}N_2O_2}+\mathrm{C_4H_7NO_4}\longrightarrow\mathrm{C_9H_{19}N_3O_6}$$

Using standard atomic masses, the component molar masses are approximately 132.16 and 133.10 g/mol, giving 265.26 g/mol for the combination. The arrow denotes the composition of the salt, not condensation with loss of water. In solution the ions dissociate and protonation changes with pH. At physiological pH ornithine is predominantly a cation because of its additional amino group, while aspartate is predominantly an anion because of its second carboxyl group. Amino-acid stereochemistry affects enzyme and transporter recognition, but it does not justify claiming that every transporter absolutely excludes every D isomer.

Oral administration exposes intestinal transport systems to the amino acids after dissolution. Cationic-amino-acid transport involves several transporter families, including systems described as y+, while acidic-amino-acid transport includes sodium-coupled EAAT transporters such as EAAT3/SLC1A1. CAT1/SLC7A1 is not a sufficient description of all apical intestinal ornithine uptake: epithelial polarity, other carriers, dietary competitors and transport gradients matter. An exact fraction assigned to a single transporter cannot be inferred from the existence of its gene.

Parenteral administration bypasses intestinal absorption; oral administration includes absorption and first-pass metabolism. These routes cannot be treated as interchangeable simply because both deliver the same amino acids. Plasma ornithine and aspartate concentrations reflect distribution and metabolism as well as absorption. A rapid plasma peak is not a measurement of mitochondrial substrate delivery or urea-cycle flux.

The pharmacokinetic literature contains small volunteer studies and reviews of older experiments. The 2019 pharmacokinetic review describes an oral study in ten healthy participants and substantial variability in exposure; this cannot establish a universal oral bioavailability of 85–90%, a single tissue distribution volume or a fixed half-life in advanced cirrhosis. The accessible record of Kowalski and Bieniecki's 2006 formulation study confirms a pharmacokinetic comparison, but not all methods needed to transplant its estimates to every formulation or patient. Diseased liver function, route, renal function and baseline amino-acid pools can alter exposure. Here pharmacokinetic estimates are interpreted as study-specific observations, not as a dosing algorithm.

Ammonia, ammonium and the clinical meaning of a measurement

The term ammonia in laboratory and clinical discussions often refers to the combined ammonia/ammonium pool. The equilibrium is:

$$\mathrm{NH_4^+}\rightleftharpoons\mathrm{NH_3}+\mathrm{H^+}$$

For an illustrative pKa of 9.25, the uncharged fraction is:

$$f_{\mathrm{NH_3}}=\frac{1}{1+10^{\mathrm{p}K_a-\mathrm{pH}}}$$

At pH 7.40 this is approximately 0.014, or 1.4%. The value changes with pH, temperature and solution conditions. It is an acid–base calculation, not a threshold for diagnosing encephalopathy. Uncharged NH3 can cross membranes readily, but NH4+ transport through channels and carriers also participates in tissue exposure; membrane movement cannot be reduced to passive NH3 diffusion alone.

Nitrogen reaches this pool through intestinal microbial metabolism, enterocyte glutamine breakdown, amino-acid catabolism and other tissue reactions. The liver normally converts much of it to urea or glutamine. Portosystemic shunts divert portal blood around hepatocytes, and loss of functional liver mass reduces metabolic capacity. Infection, gastrointestinal bleeding, constipation, dehydration, electrolyte disturbance, sedating drugs and other precipitants can worsen encephalopathy without being explained by a single ammonia concentration.

In cirrhosis, hepatic encephalopathy is a clinical syndrome assessed in its context and after considering competing causes of altered cognition. An elevated ammonia value does not independently establish its presence or grade; sample collection and handling also influence results. A normal value should prompt reconsideration of the diagnosis. EASL 2022 and the official ACG 2026 highlights distinguish clinical assessment from routine ammonia-directed treatment. This does not make ammonia biologically irrelevant. In acute liver failure, associations with cerebral edema and prognosis belong to a different clinical setting and must not be converted into a universal outpatient treatment target.

Minimal hepatic encephalopathy requires appropriate testing in a patient without obvious clinical signs. Covert encephalopathy includes minimal disease and West Haven grade I; overt encephalopathy comprises grades II–IV. PHES combines five paper-and-pencil tasks: number connection tests A and B, digit symbol, serial dotting and line tracing. Results require suitable age, education and language norms. Critical flicker frequency measures a perceptual threshold with its own test conditions; it is not a direct assay of astrocyte swelling. Improvement in one test, an ammonia measurement or quality-of-life domain is not equivalent to prevention of overt episodes or a survival benefit.

Liver zonation: two complementary systems

Blood flows through sinusoids from the portal side toward the central vein. Urea-cycle activity is distributed predominantly in periportal hepatocytes, whereas high glutamine-synthetase expression characterizes a narrow downstream pericentral population. This serial arrangement lets a broad ureagenic system process incoming nitrogen, followed by a high-affinity glutamine-producing scavenging system for residual ammonia. The zones are physiological programs, not perfectly impermeable compartments or a fixed percentage of human liver cells.

Pericentral identity is connected to local signaling, including Wnt/beta-catenin regulation, as well as blood-borne substrate and oxygen gradients. Changes in disease can alter these programs. The mouse knockout and tracer experiments of Hakvoort et al. (2017) demonstrate the importance of glutamine synthetase in ammonia handling. They do not establish a universal human allocation such as exactly 70–80% to urea and the remainder to glutamine. Enzyme affinity is also not a guarantee of sufficient whole-organ clearance when cell mass, ATP or blood access is limited.

The figure is a functional schematic; cell widths are not quantitative anatomical proportions. Urea formation and glutamine formation have different ultimate implications. Urea can leave through the kidneys in urine, although intestinal urea recycling also occurs. Glutamine temporarily packages nitrogen for transport and biosynthesis. Its later breakdown can regenerate ammonia. A rise in glutamine production must therefore be interpreted together with its downstream fate.

CPS1, NAG and mitochondrial ornithine transport

NAGS uses glutamate and acetyl-CoA to form NAG. Human NAGS was characterized biochemically by Bachmann and colleagues in 1982; recombinant mammalian NAGS studies by Caldovic et al. (2006) demonstrated stimulation by arginine. A simplified reaction is:

$$\mathrm{Glutamate}+\mathrm{Acetyl-CoA}\xrightarrow{\mathrm{NAGS}}\mathrm{NAG}+\mathrm{CoA-SH}$$

NAG binds CPS1 and enables the conformational state required for efficient catalysis. It is not incorporated into the urea molecule as a nitrogen donor. Human CPS1 uses free ammonia, bicarbonate and two ATP-dependent phosphorylation steps to produce carbamoyl phosphate. Its two phosphorylation sites and internal transfer of reaction intermediates are part of an integrated catalytic mechanism. Unlike some bacterial carbamoyl-phosphate-synthetase systems, human CPS1 should not be described as an ornithine-regulated enzyme or as using glutamine directly as its nitrogen substrate. The human structural work of de Cima et al. (2015) supports the NAG-dependent switch; a dimer in a crystallographic asymmetric unit does not establish that a functional human CPS1 dimer is obligatory.

A substrate-level representation, omitting proton-state bookkeeping, is:

$$\mathrm{NH_3}+\mathrm{HCO_3^-}+2\,\mathrm{ATP}\xrightarrow{\mathrm{CPS1}}\mathrm{Carbamoyl\ phosphate}+2\,\mathrm{ADP}+\mathrm{P_i}$$

Ornithine must reach the mitochondrial matrix for the next reaction. ORNT1, encoded by SLC25A15, participates in exchange involving ornithine and citrulline with proton coupling. The human carrier experiments of Fiermonte et al. (2003) establish transporter function; they do not justify depicting unregulated diffusion or assigning an absolute transport rate in cirrhosis. Charge balance and exchange substrates matter, so the carrier is not simply a neutral molecule swapped for a charged molecule without additional coupling.

LOLA can provide ornithine and aspartate to metabolic pools and can indirectly influence substrate availability for connected reactions. That is a reasonable basis for investigating enhanced ammonia disposal. It is not evidence of direct LOLA binding to CPS1, direct ornithine allostery at human CPS1, or guaranteed NAG production in every patient. NAGS deficiency, CPS1 deficiency, OTC deficiency and ORNT1 dysfunction are distinct disorders. NAG analogues such as carglumic acid are also pharmacologically distinct from LOLA; one cannot infer that LOLA bypasses these defects.

The urea cycle: nitrogen donors, compartments and energy

The urea cycle crosses the mitochondrial membrane. CPS1 and ornithine transcarbamylase (OTC) act in the matrix. Argininosuccinate synthetase (ASS1), argininosuccinate lyase (ASL) and arginase 1 (ARG1) complete the canonical hepatic cycle in the cytosol. Correct compartment assignments are essential: delivering extracellular aspartate is not equivalent to injecting it into a mitochondrial enzyme complex.

Two ATP molecules are converted to ADP at CPS1; one ATP is converted to AMP at ASS1. Thus three ATP molecules are used, corresponding to four high-energy phosphate-bond equivalents when ATP-to-AMP conversion and pyrophosphate hydrolysis are accounted for. The schematic table abbreviates protonation states and does not claim to be a fully ionic-balanced equation. The carbon of urea derives from bicarbonate; one nitrogen derives from ammonia and the other from aspartate. Ornithine functions as a regenerated carrier within the cycle, rather than becoming one of the two nitrogen atoms of each urea molecule.

The ASS1 reaction is especially relevant to aspartate:

$$\mathrm{Citrulline}+\mathrm{Aspartate}+\mathrm{ATP}\xrightarrow{\mathrm{ASS1}}\mathrm{Argininosuccinate}+\mathrm{AMP}+\mathrm{PP_i}$$

Pyrophosphate breakdown helps drive this biosynthetic reaction. Fumarate released by ASL can enter reactions producing malate and oxaloacetate; transamination can regenerate aspartate. This aspartate–argininosuccinate connection coordinates carbon and nitrogen metabolism, but it does not imply that all reaction fluxes increase in lockstep after supplementation.

ARG1 contains a binuclear manganese center that enables hydrolysis of arginine. Metal coordination is a structural basis of catalysis, not an indication to add manganese indiscriminately. Ornithine can also enter polyamine synthesis through ornithine decarboxylase, generating putrescine and downstream polyamines involved in growth and cellular regulation. The competing allocation of ornithine illustrates why metabolic pools matter. Polyamine biology does not prove that LOLA repairs cirrhotic tissue, reverses fibrosis or selectively accelerates regeneration. Increased substrate supply cannot replace ATP, missing enzyme activity or adequate tissue perfusion.

Transamination and the glutamate pool

Ornithine aminotransferase (OAT) is a pyridoxal-phosphate-dependent mitochondrial enzyme. It transfers the delta-amino group of ornithine to alpha-ketoglutarate, producing glutamate and glutamate-5-semialdehyde. The semialdehyde interconverts with pyrroline-5-carboxylate (P5C); further oxidation through ALDH4A1 can yield glutamate. The human OAT structural record (1998) supports the enzyme's catalytic framework.

$$\mathrm{Ornithine}+\alpha\mathrm{-ketoglutarate}\rightleftharpoons\mathrm{Glutamate\!\!\;5\!\!\;semialdehyde}+\mathrm{Glutamate}$$

The first glutamate contains the carbon skeleton of alpha-ketoglutarate; the semialdehyde/P5C retains the ornithine carbon skeleton. If the latter is also converted to glutamate, two glutamate molecules have been produced through a connected pathway, but their carbon skeletons did not both originate in one ornithine molecule. Ignoring the additional alpha-ketoglutarate would create a false carbon balance. OAT reversibility and its relationship to proline metabolism also prevent treating it as an unlimited one-way glutamate generator.

Aspartate aminotransferases connect the aspartate and glutamate pools:

$$\mathrm{Aspartate}+\alpha\mathrm{-ketoglutarate}\rightleftharpoons\mathrm{Oxaloacetate}+\mathrm{Glutamate}$$

GOT1 acts principally in the cytosol and GOT2 in mitochondria. Flux depends on compartment-specific concentrations, redox state and linked reactions. The formation of glutamate provides a plausible connection between LOLA substrates and glutamine synthesis, but the availability of alpha-ketoglutarate, energy and transporter activity determines whether the connection is productive in a particular tissue.

Glutamine synthetase and muscle compensation

Glutamine synthetase, encoded by GLUL, incorporates ammonia into glutamate using ATP:

$$\mathrm{Glutamate}+\mathrm{NH_3}+\mathrm{ATP}\xrightarrow{\mathrm{GS}}\mathrm{Glutamine}+\mathrm{ADP}+\mathrm{P_i}$$

Catalysis involves an activated gamma-glutamyl-phosphate intermediate and metal-dependent organization of substrates. The ammonia-derived nitrogen becomes the amide nitrogen of glutamine; glutamate supplies its pre-existing alpha-amino nitrogen. The extrahepatic reaction is an important buffer but requires ATP and glutamate, and its product must subsequently be transported or used.

When liver capacity falls, skeletal muscle becomes an important site of ammonia incorporation. Muscle mass therefore affects reserve capacity. Branched-chain-amino-acid transamination can provide glutamate by transferring amino groups to alpha-ketoglutarate. This connects the topic to BCAA and branched-chain ketoacid metabolism: the direction and regulation of catabolism matter more than a simplistic claim that increasing any amino acid always improves insulin sensitivity or nitrogen disposal.

Drawing alpha-ketoglutarate carbon out of the tricarboxylic-acid-cycle network is cataplerosis. It should not be called “anaplerotic depletion”; anaplerosis describes replenishment. Muscle glutamine synthesis can place demands on carbon skeletons and energy, particularly during illness and poor intake. Hyperammonemia also affects anabolic signaling and proteostasis. The cell and mouse work of Qiu et al. (2013) links ammonia exposure to NF-kappaB/myostatin signaling, offering a mechanism for muscle loss. It does not establish that LOLA restores strength, muscle area and physical function in all people with cirrhosis.

Transport out of muscle and other tissues involves multiple amino-acid carriers. An uptake transporter such as SNAT2 cannot simply be designated the sole route for glutamine export. Changes in circulating glutamine likewise do not identify which organ produced it or prove a favorable net nitrogen balance. Muscle buffering, nutritional status, protein turnover and actual renal nitrogen loss need to be distinguished.

Kidney handling: glutamine can release ammonia again

Glutamine transported in blood serves many functions: nucleotide synthesis, acid–base adaptation, immune and intestinal metabolism, and nitrogen redistribution. In the kidney, glutaminase releases the amide nitrogen as ammonia; glutamate dehydrogenase can release additional nitrogen from glutamate while producing alpha-ketoglutarate. Renal ammoniagenesis is especially important in acid–base regulation.

Some ammonia is secreted into tubular fluid and ultimately excreted as ammonium. Some can enter the renal venous circulation instead. Direct human organ-balance work reported by van de Poll and colleagues (2008) is a reminder that the kidney can contribute ammonia to systemic blood. Consequently, “LOLA makes glutamine, therefore all its nitrogen is irreversibly removed by the kidney” is not a valid inference.

Tubular transport includes mechanisms associated with NHE3 and Rh proteins, alongside segment-specific movement and trapping of ammonia/ammonium. Urine acidity, potassium balance, renal function, perfusion and the metabolic state influence the division between excretion and return to blood. A complete organ balance would compare nitrogen entering and leaving all relevant pools, not only a falling peripheral ammonia concentration. Urea and glutamine pathways can complement one another, yet their net benefits remain conditional on downstream elimination.

Nitrogen scavengers are pharmacologically different

Phenylacetate conjugates with glutamine to form phenylacetylglutamine (PAGN), which can be excreted in urine carrying two nitrogen atoms per conjugate. Benzoate uses glycine to form hippurate, carrying one nitrogen atom per conjugate. These are nitrogen-scavenging routes rather than the ordinary conversion of ammonia to urea. Ornithine phenylacetate combines an ornithine component with phenylacetate to connect nitrogen capture and conjugate elimination. The availability of glutamine and renal excretion still matters.

This mechanistic comparison does not establish clinical superiority of LOLA or of ornithine phenylacetate. In Rahimi et al. (2021), 231 hospitalized patients were included in the intention-to-treat comparison of ornithine phenylacetate with placebo. The primary time-to-clinical-response outcome did not reach statistical significance (P = 0.129). A subgroup with centrally confirmed hyperammonemia showed an exploratory signal, which cannot replace the primary result. This was not a head-to-head trial against LOLA. Mechanistic labels such as “physiological” do not prove greater efficacy or safety.

Aspartate and the malate–aspartate shuttle

The malate–aspartate shuttle transfers reducing equivalents from cytosolic NADH to mitochondrial metabolism. It does not transfer an intact NADH molecule across the inner membrane. Cytosolic MDH1 reduces oxaloacetate to malate while oxidizing NADH to NAD+; malate enters the matrix through a carrier system including the malate/alpha-ketoglutarate exchanger SLC25A11. Mitochondrial MDH2 oxidizes malate back to oxaloacetate and generates matrix NADH. GOT2 converts oxaloacetate and glutamate to aspartate and alpha-ketoglutarate; aspartate export and cytosolic GOT1 help complete the cycle.

Aspartate/glutamate carriers export aspartate in exchange for glutamate plus a proton. The correct names are aralar/AGC1, encoded by SLC25A12, and citrin/AGC2, encoded by SLC25A13. They should not be reversed. Palmieri et al. (2001) demonstrated the calcium-responsive carrier functions. Citrin is particularly relevant to hepatic aspartate availability, but external aspartate cannot be assumed to bypass every compartmental consequence of citrin deficiency.

In idealized bookkeeping, one NADH reducing-equivalent pair transferred to the respiratory chain is often associated with approximately 2.5 ATP under specified coupling assumptions. Actual yield varies with proton leak, respiratory state and the processes included in the accounting. This is not a measured ATP gain from taking LOLA. Furthermore, the older absolute assertion that the inner membrane admits no NAD+ must be corrected: Luongo et al. (2020) identified SLC25A51 as a transporter of intact NAD+. NAD+ transport and the shuttle's transfer of NADH reducing equivalents are different processes.

Glutathione, oxidative stress and the brain

Glutamate is one precursor of glutathione, a tripeptide containing glutamate, cysteine and glycine. Glutamate–cysteine ligase and glutathione synthetase use ATP in two synthesis steps; adequate cysteine, glycine and enzyme regulation are necessary. Glutathione peroxidases use reduced glutathione during peroxide reduction, generating oxidized glutathione, which glutathione reductase can reduce with NADPH.

$$\mathrm{ROOH}+2\,\mathrm{GSH}\longrightarrow\mathrm{ROH}+\mathrm{H_2O}+\mathrm{GSSG}$$ $$\mathrm{GSSG}+\mathrm{NADPH}+\mathrm{H^+}\longrightarrow2\,\mathrm{GSH}+\mathrm{NADP^+}$$

The substrate ROOH denotes a peroxide, with enzyme specificity determining which species can be reduced. GPX4 and lipid-peroxide control explain why the relevant enzyme and lipid compartment matter. GPX4's role in reducing phospholipid hydroperoxides does not establish universal destruction of peroxynitrite by any glutathione-peroxidase pathway.

Peroxynitrite chemistry can nitrate tyrosine residues; nitration is distinct from S-nitrosylation of cysteine. Reactive oxygen and nitrogen species can damage proteins, lipids and mitochondrial function in ammonia-related experimental systems. Najmi et al. (2010) measured hepatic oxidative-stress markers and glutathione in a thioacetamide rat model. Such findings support a preclinical hypothesis of improved antioxidant status, not a quantified increase of glutathione in the human brain or complete prevention of cerebral oxidative injury.

Brain amino-acid pools are compartmentalized by the blood–brain barrier and local metabolism. More glutamate substrate in peripheral tissue does not guarantee more astrocyte glutathione, especially when glutamate transport is tightly controlled. Glutamate is also an excitatory neurotransmitter. A peripheral biochemical intervention must therefore not be described as direct, unlimited delivery of antioxidant precursor to the brain.

Astrocytes convert ammonia to glutamine, and intracellular glutamine can contribute to osmotic stress. In experimental “Trojan horse” models, mitochondrial glutamine breakdown regenerates ammonia and promotes oxidative stress and permeability changes. The cultured-astrocyte work associated with Rama Rao, Jayakumar and Norenberg (2003) belongs to this mechanistic literature; it does not demonstrate that LOLA prevents 100% of mitochondrial permeability-transition events. Astrocytes are central to brain nitrogen handling, but other cell types and pathways also participate.

The mitochondrial permeability-transition pore is a regulated phenomenon involving calcium, redox state and mitochondrial conditions. Cyclophilin D modulates susceptibility; the full structural identity and context of the pore remain subjects of investigation. A fixed list of pore components cannot be turned into a proven LOLA drug target. AQP4 water-channel distribution, neurosteroid signaling involving TSPO, and altered transport of tryptophan and other large neutral amino acids provide additional experimental approaches to encephalopathy. Serotonin and kynurenine pathways are possible contributors, not established biomarkers showing that LOLA has corrected the entire syndrome. Effects on these pathways must be demonstrated rather than inferred from a fall in ammonia.

The gut: ammonia production and uncertain microbiome effects

Microbial ureases hydrolyze urea and can regenerate ammonia; intestinal glutamine metabolism also contributes nitrogen. Urea delivered to the intestine is therefore part of nitrogen recycling, not simply a permanently detoxified pool. Improving hepatic ureagenesis does not by itself demonstrate suppression of bacterial urease. Enterobacteriaceae should not be collectively called obligate anaerobes, and bacterial taxonomy alone does not quantify ammonia production.

Horvath et al. (2022) compared 15 LOLA-treated patients with 15 matched patients in a retrospective study. Microbiome and metabolome associations are hypothesis-generating; treatment allocation and other clinical differences prevent a direct causal conclusion. A newer single-center observational phase 4 study, published in Clinical Nutrition 56 (2026), included 65 participants, of whom 52 completed follow-up. Its primary Flavonifractor endpoint was not met. Romboutsia decreased and Enterococcus increased; the findings do not support indiscriminate claims of a globally normalized microbiome. Improvements in vitality concerned one of eight quality-of-life domains. Exploratory muscle findings in subgroups and changes in diamine oxidase or lipopolysaccharide-binding protein cannot establish healed intestinal permeability, reduced infection or improved survival. The prospective study lacked a concurrent control group.

The gut–liver–muscle system remains a reasonable framework for research, but each arrow requires its own evidence. A plausible reduction in ammonia burden, a microbial abundance change and a clinical episode prevented cannot be treated as the same event.

What randomized trials actually measured

Study exposure below is included to identify the experiments, not to provide a treatment schedule. Oral and intravenous products, clinical settings and background treatment differ. Numbers are retained only when the accessible primary report supports them.

The difference between the Sidhu and Jain trials is substantive, not a contradiction to conceal: populations, background care and timing differ. The background in Sidhu's study was not the lactulose–rifaximin combination used by Jain. Apparent benefit during the first few days is different from a prespecified day-5 comparison. A result that does not reach statistical significance is not proof of identical treatments, but it does not support declaring the primary endpoint successful.

For the recurrence trial, a simple observed-proportion calculation gives an absolute difference of approximately 15.4 percentage points. The reciprocal is about 6.5, or roughly seven treated patients over that study's six-month period per recurrence avoided, if the effect is causal and transferable. This descriptive calculation uses observed event proportions; it is not identical to the time-to-event hazard ratio and should not be transported to every baseline risk or treatment background:

$$\mathrm{ARR}=\frac{20}{72}-\frac{9}{73}\approx0.1545,\qquad\mathrm{NNT}\approx\frac{1}{\mathrm{ARR}}\approx6.5$$

Here ARR is absolute risk reduction and NNT is the corresponding number needed to treat under the stated assumptions. Differences in follow-up, censoring and analysis populations limit a simple proportion-based summary.

Goh et al.'s Cochrane review (2018) identified 36 randomized trials, with outcome data from 29 trials and 1,891 participants. Possible pooled benefits were accompanied by very low certainty and were not robustly confirmed in analyses emphasizing lower risk of bias. Later trials provide additional information, but do not retroactively remove bias from older evidence. Meta-analyses can differ because they include different studies, routes, outcomes and methods; a favorable pooled estimate should not replace appraisal of these choices.

Guidelines, combination treatment and clinical boundaries

The 2014 AASLD/EASL guideline described intravenous LOLA as an alternative or additional option in patients not responding to conventional treatment. Its historical assessment of oral treatment predates newer oral trials and should not be cited as if no subsequent evidence exists. EASL 2022 and the ACG 2026 guidance place management in a broader clinical framework: establish the syndrome, identify precipitants, and distinguish overt episodes, recurrence and covert disease. The official ACG 2026 highlights do not support routine treatment titration to an ammonia number or routine treatment of all covert cases solely to prevent overt encephalopathy.

Lactulose and rifaximin address different aspects of the syndrome and have established roles within clinical care. An adjunctive LOLA trial conducted on their background can answer whether adding LOLA helped in that specific population; it does not demonstrate that LOLA can replace them. Nor does it prove a universal three-drug biochemical synergy. Albumin may be used for specific indications or investigated in related settings, but this is not evidence for an automatic LOLA–lactulose–rifaximin–albumin protocol. Adequate nutrition and preservation of muscle matter; routine protein restriction can worsen muscle reserve and is discouraged in current guidance.

Published doses and durations in the table identify research exposures. They are not recommendations for loading doses, infusion dilution, a fixed 20–40 g/day regimen for everyone, or an ammonia target below 50 micromol/L. Product, route, severity, contraindications and local prescribing information determine clinical use. A patient with new confusion or reduced consciousness requires assessment of the cause and severity rather than selection of a supplement from a mechanistic diagram.

Safety and renal impairment

The manufacturer's core prescribing information identifies severe renal impairment as a contraindication and gives a serum creatinine above 3 mg/100 mL as a product-level guide. This should be reported as a prescribing-information criterion, not as a universal renal threshold applicable to every country, formulation or patient. Creatinine concentration also does not fully capture kidney function in someone with low muscle mass. Hypersensitivity to the product is another contraindication.

Gastrointestinal adverse effects and route-dependent tolerability require attention. Intravenous treatment has administration-specific constraints that cannot be reproduced safely from a research table. Pregnancy, breastfeeding and pediatric use have limited evidence in the product information; the absence of a strong trial signal is not proof of safety in these groups. Likewise, the fact that the constituents are amino acids does not demonstrate an absence of drug interactions, complete freedom from CYP-related effects, or a universal adverse-event rate of 1–3%.

Renal dysfunction affects downstream nitrogen handling and the interpretation of glutamine-based pathways. Hyperammonemia due to an inherited metabolic disorder differs from cirrhosis-associated encephalopathy; treating one by analogy with the other risks ignoring the specific defect. The biochemical discussion here does not establish an approved indication for every urea-cycle disorder, nor an official contraindication for all such disorders unless the relevant product information states one.

MASLD, muscle outcomes and hepatoprotection hypotheses

Older studies use the terms NAFLD and NASH, while contemporary terminology includes metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH). Terminology changes should not hide differences in the population definitions. Improved liver enzymes, altered oxidative-stress markers or a plausible glutathione pathway do not demonstrate fibrosis regression, improved portal microcirculation or prevention of liver-related death.

Pichon et al. (2022) studied Alms1-mutant foz/foz mice fed a high-fat diet. Early treatment and treatment of established disease were distinct experimental settings. Muscle/myosteatosis findings in the early setting were not accompanied by improvement of ammonia metabolism or liver disease. Micro-CT muscle density and area are not equivalent to human strength or functional recovery. These experiments therefore do not prove that LOLA reverses human MASH fibrosis or cures cirrhotic sarcopenia. Exploratory muscle findings from an uncontrolled human microbiome study have different limitations again.

The possibility that reducing an ammonia burden could help muscle metabolism is biologically reasonable. To establish a clinical muscle benefit, studies need relevant endpoints such as muscle mass, strength, performance and patient-centered function, alongside nutrition and disease severity. A serum-ammonia change is an insufficient substitute for those outcomes.

Acute liver failure and transplantation

Acute liver failure can progress rapidly, and cerebral edema, multiorgan dysfunction and the need for transplantation distinguish it from stable chronic cirrhosis. Rose et al. (1999) reported rat-model findings involving brain ammonia and edema. The human randomized study by Acharya et al. (2009), however, did not confirm an ammonia or survival benefit. Animal mechanisms must not override that clinical result or justify delaying etiology-specific care, intensive monitoring or transplant assessment.

After transplantation, liver function, renal function, immunosuppression and the cause of any hyperammonemia determine the clinical question. The existence of perioperative nitrogen stress is not evidence that LOLA improves transplant outcomes. A general claim of proven post-transplant neuroprotection or survival benefit requires direct evidence that the accessible studies considered here do not provide.

How this article was prepared

Prepared on 8 October 2026. This is a narrative scientific explanation with targeted checks of primary biochemical studies, randomized trials, official guidance and prescribing information. It is not a systematic review, a new GRADE assessment, peer review or clinical validation. Trial outcomes, comparators, years and identifiers were checked where accessible; contradictory and negative results were retained. Some full texts were unavailable, so metadata, abstracts or accessible selected passages were used; exact inaccessible methods were not verified. Experimental mechanisms are distinguished from human treatment outcomes, and research exposures are distinguished from prescribing instructions.